NCT01933035

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: Beth Israel Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another. To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.

Detailed description

Patient to be registered at the Haematology-Oncology department Mount Sinai Roosevelt Hospital. Inclusion criteria are as follows: All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by response to IVIG, glucocorticoids, or WinRho and exclusion of all other possible causes of thrombocytopenia Confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\]. Chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.

Conditions

• Immune Thrombocytopenia
• Chemotherapy Induced Thrombocytopenia
• Myelodysplasia
• Aplastic Anaemia

Interventions

Type	Name	Description
OTHER	Immune Thrombocytopenics	Full blood count with extended platelet parameters
OTHER	Hypo-proliferative thrombocytopenics	Full blood count with extended platelet parameters
OTHER	Control Population	Full blood count with extended platelet parameters

Timeline

• Start date: 2013-10-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2013-08-30
• Last updated: 2016-05-17

Locations

1 site across 1 country: United States